Regeneron Pharmaceuticals Stock News

Related Stocks: REGN , CLX , PSA , GIS , WAT , CHD , BDX , UPS , AZO , DGX , CERN , K , NVDA , SAM , BKNG , SWKS , AMAT , SFM ,

The stock price of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) increased by 1.79% today. This is why it happened.

CNBC's Jim Cramer and the 'Squawk on the Street' team discuss new studies out of Israel looking at how well Pfizer and BioNTech's Covid-19 booster works in people over age 50.

The Goldman Sachs Group assumed coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report published on Monday, Price Targets.com reports. The brokerage issued a buy rating and a $824.00 price objective on the biopharmaceutical companys stock. Several other brokerages also recently commented on REGN. Cantor Fitzgerald boosted their price objective on Regeneron Pharmaceuticals from []

Venture Visionary Partners LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,682 shares of the biopharmaceutical companys stock after purchasing an additional 204 shares during the quarter. Venture Visionary Partners []

Related Stocks: KWEB , FB , CMA , ALL , CRM , DOW , IJH , REGN , EOG , BAB , GE , CVNA , ATVI , AEP , WORK , PAYC , ATO , CXP ,

The Goldman Sachs Group began coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a note issued to investors on Monday, The Fly reports. The brokerage set a buy rating on the biopharmaceutical companys stock. Other equities research analysts also recently issued reports about the company. Piper Sandler increased their price target on Regeneron Pharmaceuticals from []

Should investors be watching these biotech stocks with all the current focus on the Omicron Covid variant?

The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have received an $824 price target from Goldman Sachs. These are the details.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, December 1st. The stock was sold at an average price of $637.53, for a total value of $63,753.00. The transaction was disclosed in a document filed with the SEC, which is available through []

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Marion Mccourt sold 1,000 shares of the stock in a transaction dated Wednesday, December 1st. The stock was sold at an average price of $639.13, for a total value of $639,130.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Marion []

TARRYTOWN, N.Y. , Dec. 3, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the H.C. Wainwright & Co. event – Unlocking the Full Potential of RNAi With World-Class Novel Target Identification: Regeneron Genomics and

The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing u

Related Stocks: SBAC , VRTX , REGN , HUM , SAIC , FIS , STT , TFC , TNET , CASH , CVLT , SWIR , ATVI , AZO , AKAM , BJ , SYY , ZBRA , QTS , OTEX , ZNGA , HAE , STRA , CLDR ,

Regeneron has made billions from its Covid-19 drug, and it has new drugs like Dupixent that could make many billions more. The post Regeneron: Surfing on Covid, With More Under the Surface appeared fi